QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
NASDAQ:VCNX

Vaccinex (VCNX) Stock Forecast, Price & News

$1.13
-0.07 (-5.83%)
(As of 05/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.09
$1.17
50-Day Range
$1.12
$1.46
52-Week Range
$0.90
$3.28
Volume
277,779 shs
Average Volume
854,174 shs
Market Capitalization
$48.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.08
30 days | 90 days | 365 days | Advanced Chart
Receive VCNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

Vaccinex logo

About Vaccinex

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCNX
Employees
39
Year Founded
N/A

Sales & Book Value

Annual Sales
$900 thousand
Book Value
$0.38 per share

Profitability

Net Income
$-22.38 million
Pretax Margin
-40,802.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,356,000
Market Cap
$48.21 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/31/2022
Today
5/23/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

961st out of 1,423 stocks

Pharmaceutical Preparations Industry

479th out of 678 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -













Vaccinex (NASDAQ:VCNX) Frequently Asked Questions

Are investors shorting Vaccinex?

Vaccinex saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 564,800 shares, a decrease of 23.3% from the April 15th total of 736,100 shares. Based on an average daily volume of 299,800 shares, the days-to-cover ratio is currently 1.9 days. Approximately 4.2% of the company's shares are short sold.
View Vaccinex's Short Interest
.

When is Vaccinex's next earnings date?

Vaccinex is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Vaccinex
.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) announced its quarterly earnings data on Thursday, March, 31st. The company reported ($0.15) earnings per share (EPS) for the quarter.
View Vaccinex's earnings history
.

Who are Vaccinex's key executives?
Vaccinex's management team includes the following people:
  • Dr. Maurice Zauderer Ph.D., Co-Founder, CEO, Pres & Director (Age 76, Pay $374.9k) (LinkedIn Profile)
  • Mr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 48, Pay $242.15k)
  • Dr. Ernest S. Smith Ph.D., Sr. VP of Research & Chief Scientific Officer (Age 50, Pay $264.74k)
  • Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
  • Dr. Elizabeth E. Evans Ph.D., COO and Sr. VP of Discovery & Translational Medicine (Age 49)
  • Dr. John E. Leonard Ph.D., Sr. VP of Devel. (Age 75)
What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

(VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a variety of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (4.88%), Vanguard Group Inc. (1.70%), Worth Venture Partners LLC (0.16%), Group One Trading L.P. (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Company insiders that own Vaccinex stock include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer and Strydonck Gerald E Van.
View institutional ownership trends for Vaccinex
.

Which institutional investors are selling Vaccinex stock?

VCNX stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., and Simplex Trading LLC.
View insider buying and selling activity for Vaccinex
or view top insider-selling stocks.

Which institutional investors are buying Vaccinex stock?

VCNX stock was bought by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Vanguard Group Inc., and Worth Venture Partners LLC. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer, and Strydonck Gerald E Van.
View insider buying and selling activity for Vaccinex
or or view top insider-buying stocks.

How do I buy shares of Vaccinex?

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $1.13.

How much money does Vaccinex make?

Vaccinex has a market capitalization of $48.21 million and generates $900 thousand in revenue each year. The company earns $-22.38 million in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does Vaccinex have?

Vaccinex employs 39 workers across the globe.

What is Vaccinex's official website?

The official website for Vaccinex is www.vaccinex.com.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at (585) 271-2700, via email at [email protected], or via fax at 585-271-2765.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.